U.S. FDA Gives Its Nod to Bimekizumab-bkzx (Bimzelx, UCB) for HS
The U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx, UCB) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Bimekizumab, an interleukin 17F (IL-17F) and IL-17A blocker, is now the third medication approved for HS, joining adalimumab (Humira, AbbVie) and its biosimilars and secukinumab (Cosentyx, Novartis). “The approval of BIMZELX in moderate-to-severe […]